© 2004 by Oxford University Press
© 2004 Oxford University Press
EDITORIAL |
Outcome Prediction and the Future of the TNM Staging System
Correspondence to: Harry B. Burke, MD, PhD, George Washington University School of Medicine, 2150 Pennsylvania Ave NW, Ste. 2-105, Washington, DC 20037 (e-mail: hburke@mfa.gwu.edu)
| The first 150 words of the full text of this article appear below. |
The prediction of patient prognosis has always been essential to the practice of medicine. By the early 20th century, Halsted (1) and others believed that solid tumors spread contiguously over time through a series of stages, from the primary tumor site, through the lymphatics, to distant organs, with each stage conferring an increasingly poor prognosis. A corollary of this view, supported by later research, was that, at diagnosis (clinical tumor–node–metastasis [TNM] stage) or after surgery (pathologic TNM stage), tumor size or location (T), regional lymph node involvement (N), and distant metastases (M) were indices of disease spread and could be used to predict patient outcome.
In 1953, the French surgeon Pierre Denoix proposed to the Union Internationale Centre le Cancer that these three factors be standardized and integrated into a prognostic system that could be used, with some accommodation for anatomic site, across all solid tumors (2
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. Onitilo, J. M. Engel, C. I. Lundgren, P. Hall, L. Thalib, and S. A.R. Doi Simplifying the TNM System for Clinical Use in Differentiated Thyroid Cancer J. Clin. Oncol., April 10, 2009; 27(11): 1872 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S.-C. Wong, M.-T. Cheung, B. B.-Y. Ma, E. Pun Hui, A. C.-L. Chan, C.-K. Chan, K.-C. Lee, W. Cheuk, M. Y.-Y. Lam, M. C.-K. Wong, et al. Isolated Tumor Cells and Circulating CK20 mRNA in pN0 Colorectal Cancer Patients International Journal of Surgical Pathology, April 1, 2008; 16(2): 119 - 126. [Abstract] [PDF]
|
|
|
|
 |
|
 S.-Y. Jeong, D. B. Chessin, D. Schrag, E. Riedel, W. D. Wong, and J. G. Guillem Re: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging J Natl Cancer Inst, November 16, 2005; 97(22): 1705 - 1706. [Full Text] [PDF]
|
|
|
|
|
|
H. B. Burke RESPONSE: Re: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging J Natl Cancer Inst, November 16, 2005; 97(22): 1707 - 1707. [Full Text] [PDF]
|
|
|
|
|
|
S. B. Edge, L. H. Sobin, D. L. Page, M. K. Gospodarowicz, F. L. Greene, and D. P. Winchester Re: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging J Natl Cancer Inst, March 16, 2005; 97(6): 463 - 464. [Full Text] [PDF]
|
|
|
|
|
|
J. B. O'Connell, M. A. Maggard, and C. Y. Ko RESPONSE: Re: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging J Natl Cancer Inst, March 16, 2005; 97(6): 464 - 464. [Full Text] [PDF]
|
|